(2-methyl-6-nitro-phenyl)-pyruvic acid | 70467-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-methyl-6-nitro-phenyl)-pyruvic acid
• 英文别名: (2-Methyl-6-nitro-phenyl)-brenztraubensaeure；(6-methyl-2-nitrophenyl)pyruvic acid；2-Methyl-6-nitro-α-oxobenzenepropanoic acid；6-Methyl-2-nitrophenylpyruvic acid；3-(2-methyl-6-nitrophenyl)-2-oxopropanoic acid
• CAS: 70467-01-5
• 化学式: C₁₀H₉NO₅
• 分子量: 223.185
• InChiKey: HCRKYXZTNLIMMF-UHFFFAOYSA-N

物化性质

• 沸点：
  399.7±30.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2-methyl-6-nitro-phenyl)-pyruvic acid 在 喹啉 、 ammonium hydroxide 、 iron hydroxide 、 copper(l) chloride 作用下， 生成 4-甲基吲哚
  参考文献：
  名称：

  Andrisano; Vitali, Gazzetta Chimica Italiana, 1957, vol. 87, p. 949,953, 958

  摘要：

  DOI：
• 作为产物：
  描述：

  3-硝基邻二甲苯 、 草酸二乙酯 在 sodium hydroxide 、 sodium 作用下， 以 乙醇 、 水 为溶剂， 以61%的产率得到(2-methyl-6-nitro-phenyl)-pyruvic acid
  参考文献：
  名称：

  Indole- and benzimidazole-substituted quinoline derivatives

  摘要：

  式##STR1##中X，R.sub.1，R.sub.2，R.sub.3，R.sub.4，R.sub.5，R.sub.6和R.sub.7的化合物，如本文所定义。这些化合物抑制肾素-血管紧张素系统的作用，因此例如作为降压药物是有用的。

  公开号：

  US05616591A1

文献信息

• Biphenyl-substituted quinoline derivatives
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US06117885A1

  公开（公告）日：2000-09-12

  Compounds of the formula ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, A, B, D and E are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.

  式为##STR1##的化合物，其中X，R.sub.1，R.sub.2，R.sub.3，R.sub.4，R.sub.5，R.sub.6，A，B，D和E的定义如本文所述。这些化合物抑制肾素-血管紧张素系统的作用，因此例如作为降压药物是有用的。
• Indoloylguanidine derivatives
  申请人：Sumitomo Pharmaceuticals Co., Ltd.

  公开号：US06248772B1

  公开（公告）日：2001-06-19

  Novel indoloylguanidine derivatives shown by formula (1), wherein R1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: —OR3, —NR6R7, —SO2NR6R7 or —S(O)nR40; and R2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: —CH2R20; and which inhibit the Na+/H+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na+/H+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caused by excessive cell proliferation.

  化合物式（1）所示的新型吲哚基胍衍生物，其中R1表示一个或多个相同或不同的取代基，选自以下组成的群体：氢原子、烷基、取代烷基、烯基、炔基、环烷基、卤素原子、硝基、酰基、羧基、烷氧羰基、芳香基和由式子—OR3、—NR6R7、—SO2NR6R7或—S(O)nR40表示的基团；R2表示氢原子、烷基、取代烷基、环烷基、羟基、烷氧基或由式子—CH2R20表示的基团；这些化合物抑制Na+/H+交换活性，对于治疗和预防由增加的Na+/H+交换活性引起的疾病，如高血压、心律不齐、心绞痛、心肌肥厚、糖尿病、缺血或缺血再灌注相关的疾病、脑缺血性疾病或由过度细胞增殖引起的疾病有用。
• Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0556060A1

  公开（公告）日：1993-08-18

  Compounds of the formula wherein X, R₁, R₂, R₃, R₄, R₅, R₆, A, B, D and E are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.

  式中的化合物 其中 X、R₁、R₂、R₃、R₄、R₅、R₆、A、B、D 和 E 如本文所定义。这些化合物可抑制血管紧张素 II 的作用，因此可用作降压药等。
• US6169107
  申请人：——

  公开号：——

  公开（公告）日：——
• Different sensitivities to competitive inhibition of benzodiazepine receptor binding of11C-iomazenil and11C-flumazenil in rhesus monkey brain
  作者：Osamu Inoue、Rie Hosoi、Kaoru Kobayashi、Takashi Itoh、Antony Gee、Kazutoshi Suzuki

  DOI：10.1007/bf02988604

  日期：2001.4

  The in vivo binding kinetics of C-11-iomazenil were compared with those of C-11-flumazenil binding in rhesus monkey brain. The monkey was anesthetized with ketamine and intravenously injected with either C-11-iomazenil or C-11-flumazenil in combination with the coadministration of different doses of non-radioactive flumazenil (0, 5 and 20 mug/kg). The regional distribution of C-11-iomazenil in the brain was similar to that of C-11-flumazenil. but the sensitivity of C-11-iomazenil binding to competitive inhibition by non-radioactive flumazenil was much less than that of C-11-flumazenil binding. A significant reduction in C-11-flumazenil binding in the cerebral cortex was observed with 20 mug/kg of flumazenil, whereas a relatively smaller inhibition of C-11-iomazenil binding in the same region was observed with the same dose of flumazenil. These results suggest that C-11-flumazenil may be a superior radiotracer for estimating benzodiazepine receptor occupancy in the intact brain.